Cutting off cancer cells’ access to fats may enhance cancer therapy

The addition of androgen receptor signaling inhibitors (ARSIs) alongside standard androgen deprivation therapy (ADT) in advanced prostate cancer was associated with a significantly increased risk

An increased risk of early death has created uncertainty about the risk-benefit ratio of two CAR T-cell therapies for relapsed/refractory multiple myeloma, which an FDA